SmartTouch Catheter in Ablation of Ventricular Tachycardia
NCT ID: NCT01639365
Last Updated: 2015-09-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
20 participants
OBSERVATIONAL
2012-07-31
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Late Potentials and Ablation Index in Ventricular Tachycardia Ablation
NCT03437408
Early Ablation Therapy for the Treatment of Ischemic Ventricular Tachycardia in Patients With Implantable Cardioverter Defibrillators
NCT01557842
Computed Tomography-Guided Catheter Ablation for Ventricular Tachycardia
NCT05225935
Ultra-high Density Mapping With Multielectrode Catheter vs Conventional Point by Point Mapping for Ventricular Tachycardia Substrate Ablation
NCT02083016
Modification of Rhythmic Risk Assessment by Ventricular Tachycardia Ablation
NCT03453645
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A widespread technique for ablation of ventricular tachycardias (VT) in patients with cardiomyopathies or ischemic disease consists on the creation of an electroanatomic map to delineate scar areas without electric activity and to look for areas of surviving myocardium inside, at the borders or between the scars, operating as a slow conduction channel in a reentry circuit and playing an essential role in the genesis of VTs. The distinction between scar and normal tissue is predominantly based on the voltage of the unipolar or bipolar electrograms (EGM) recorded at the tip of the ablation catheter. However, the amplitude of the electrogram depends critically on the distance between the electrode and the source of the electric field, in this case the myocardial tissue. The lack of contact between the catheter and the endocardium will reduce the EGM voltage and may induce to interpret a normal EGM point as a low-voltage point, leading to an erroneous delineation of the real scar areas and eventually missing electrically active myocardial paths. Thus a good physical contact between the catheter and the tissue is a prerequisite to obtain a reliable voltage map and to correctly identify scars and areas potentially involved in the VT maintenance. A direct information on the force applied at the tip of the catheter may avoid the interpretation of areas with no-contact induced low-voltage as scars.
Hypothesis.
The hypothesis of the study is that the information on the force exerted by the catheter tip obtained from the SmartTouch technology may improve the assessment of the scar areas during electroanatomical mapping in patients with VT due to ischemic disease or cardiomyopathy.
Study objectives and endpoints.
Two are the main objectives of this study:
1. To compare the areas of scar (defined as a low-voltage threshold) obtained from the conventional voltage map with those obtained after the contact map information is available to the operator.
2. To determine if the availability of the contact information to the operator allows an improvement of the electroanatomic map by correcting the points taken in no-contact areas.
Study protocol.
1. Inclusion criteria.
Consecutive patients with ventricular arrhythmias due to ischemic heart disease or dilated cardiomyopathy undergoing VT ablation will be included in the study.
Exclusion criteria will be age \<18 years, absence of signed informed consent or critical clinical status that precludes a detailed mapping procedure.
2. Study design and duration.
The study is planned as a prospective, one-center, non-randomized study. As the objectives are purely descriptive no formal calculation of the sample size has been performed. Considering the inclusion criteria and the frequency of this type of studies in our unit a number of 20 to 30 patients is estimated to be included in 12 months. We believe that this number of patients is reasonable to estimate the value of the contact map to delineate scars from a clinical point of view.
3. Protocol and procedure.
Our standard approach to ischemic VT ablation begins with the acquisition of a voltage map of the left ventricle during sinus rhythm of fixed pacing from the right ventricular apex using the CARTO-3 navigation system and a Navistar irrigated catheter. During the acquisition, points with fragmented or delayed potentials are tagged as areas of potential interest for ablation. Once the map is completed we adjust the color code of the voltage map trying to decide the areas of dense scar and to look for potential narrow paths inside or between the areas of scar. After adjusting the map in this way we proceed to the ablation, which is performed during induced VT or guided by the anatomical and electrical information in case of non-inducible or non-tolerated VTs. Pace-mapping is eventually used if a 12-lead ECG of the clinical VT is available.
For the patients included in the study the voltage map will be acquired in the same way using the Thermo-Cool Smart Touch catheter. The force information will be recorded by the system but will not be available to the operator during the map acquisition. The completed voltage map with the areas defined as dense scar by the operator, the isthmuses found inside or between scars and the areas with fragmented or delayed potentials will be saved as the control map. Following this step the contact map will be available to the operator to be compared with the control map and further mapping and point acquisition will be allowed to correct the areas previously acquired with poor or no contact. The final map after corrections have been made will be saved as the corrected map. The ablation procedure will then be performed as usual.
4. Map analysis
The comparison of the maps will be done in a deferred way. First, the control map and the contact map will be compared. The area without contact in the pressure map will be estimated. Each point inside this area will be classified as dense scar, low-voltage point or normal voltage point according to the properties of the point in the control map. We will determine in this way how are classified the areas without contact when no pressure information is available, and how many non-contact points are falsely assumed to be dense scar. The areas of "real" dense scar and "assumed, non-contact" dense scar will be estimated as well. This step of the analysis will give information on how many low-voltage areas of the standard electroanatomic map may not be reliable due to lack of an appropriate contact.
The control and the corrected map will then be compared. The areas and the number of points defined as dense scar by the operator in both maps will be compared and the points changing their status as scar, low or normal voltage from the control to the corrected map will be annotated as well. Finally, the differences in the potential isthmuses depicted in both maps will be analyzed. These comparisons will give information on how much the standard electroanatomic map can be improved when the force information is added.
5. Patient consent.
The study will be presented to the ethics committee of our centre for approval. A written, informed consent will be required to be signed by the patient before entering the study.
6. Time schedule
The recruitment of patients will start as soon as the project is approved by Biosense Webster and by the local ethics committee. The inclusion period would be 12 months. Data analysis will be performed during the study period, making the final results available shortly after the end of the study. An additional 6 month period is expected to report and publish the results in international cardiology journals.
7. Privacy policy
All the patient's data will remain in the hospital files and will not be transmitted to any external subject. A code will be assigned to each patient in order to allow the analysis of the data in an anonymous way .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biosense Webster, Inc.
INDUSTRY
Hospital Universitario Virgen de la Arrixaca
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Arcadio Garcia Alberola
Professor of Cardiology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arcadi Garcia-Alberola, MD
Role: PRINCIPAL_INVESTIGATOR
Hospital Universitario Virgen de la Arrixaca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Virgen de la Arrixaca
Murcia, Murcia, Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sanchez Munoz JJ, Penafiel Verdu P, Martinez Sanchez J, Salar Alcaraz M, Valdes Chavarri M, Garcia Alberola A. Usefulness of the contact force sensing catheter to assess the areas of myocardial scar in patients with ventricular tachycardia. Rev Esp Cardiol (Engl Ed). 2015 Feb;68(2):159-60. doi: 10.1016/j.rec.2014.09.011. Epub 2014 Dec 12. No abstract available.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IIS-176
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.